{"id":5451,"date":"2022-11-02T17:52:35","date_gmt":"2022-11-02T17:52:35","guid":{"rendered":"https:\/\/blogs.sld.cu\/oserranob\/?p=5451"},"modified":"2022-11-02T17:52:35","modified_gmt":"2022-11-02T17:52:35","slug":"oportunidades-y-potencialidades-de-biobancos","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/oserranob\/2022\/11\/02\/oportunidades-y-potencialidades-de-biobancos\/","title":{"rendered":"Oportunidades y potencialidades de biobancos"},"content":{"rendered":"<p>&#8211; <a href=\"https:\/\/www.cell.com\/cell-genomics\/fulltext\/S2666-979X(22)00141-0\">Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease<\/a>. Cell Genomics, 2022;2(10):100192.<br \/>\n&#8211; <a href=\"https:\/\/www.cell.com\/cell-genomics\/fulltext\/S2666-979X(22)00144-6\">Proteome-wide Mendelian randomization in global biobank meta-analysis reveals multi-ancestry drug targets for common diseases<\/a>. Cell Genomics, 2022;2(10):100195.<br \/>\n&#8211; <a href=\"https:\/\/www.cell.com\/cell-genomics\/fulltext\/S2666-979X(22)00139-2\">A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis<\/a>. Cell Genomics, 2022;2(10):100190.<br \/>\n&#8211; <a href=\"https:\/\/www.cell.com\/cell-genomics\/fulltext\/S2666-979X(22)00125-2\">Best practices for multi-ancestry, meta-analytic transcriptome-wide association studies: Lessons from the Global Biobank Meta-analysis Initiative<\/a>. Cell Genomics, 2022;2(10):100180.<br \/>\n&#8211; <a href=\"https:\/\/www.cell.com\/cell-genomics\/fulltext\/S2666-979X(22)00138-0\">Genome-wide study on 72,298 individuals in Korean biobank data for 76 traits<\/a>. Cell Genomics, 2022; DOI: https:\/\/doi.org\/10.1016\/j.xgen.2022.100189.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease. Cell Genomics, 2022;2(10):100192. &#8211; Proteome-wide Mendelian randomization in global biobank meta-analysis reveals multi-ancestry drug targets for common diseases. Cell Genomics, 2022;2(10):100195. &#8211; A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. Cell Genomics, 2022;2(10):100190. &#8211; Best practices for multi-ancestry, [&hellip;]<\/p>\n","protected":false},"author":125,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[15,21,29,39],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/5451"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/comments?post=5451"}],"version-history":[{"count":1,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/5451\/revisions"}],"predecessor-version":[{"id":5456,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/5451\/revisions\/5456"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/media?parent=5451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/categories?post=5451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/tags?post=5451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}